RVMD – revolution medicines, inc. (US:NASDAQ)
Stock Stats
News
MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 [Yahoo! Finance]
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $92.00 to $122.00. They now have an "overweight" rating on the stock.
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed [Yahoo! Finance]
Revolution Medicines (NASDAQ:RVMD) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Form 4 Revolution Medicines, For: Jan 21 Filed by: Cislini Jeff
Form 144 Revolution Medicines, Filed by: Cislini Jeff
Form 4 Revolution Medicines, For: Jan 07 Filed by: Horn Margaret A
Form 4 Revolution Medicines, For: Jan 07 Filed by: Anders Jack
Form 144 Revolution Medicines, Filed by: Anders Jack
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.